Improved Sleep Quality and Work Performance Among Shift Workers Consuming a “Foods with Function Claims” Containing Asparagus Extract

Sakai, Saki; Nagata, Michio; Nagata, Tomohisa; Mori, Koji

doi:10.7888/juoeh.43.15

Cited by 2 publications

(1 citation statement)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been shown to enhance heat shock protein 70 (HSP70)-inducing activity and promote antistress effects in mice [ 4 ] and autonomic nerve regulation effects in humans [ 4 , 5 ]. A human intervention study showed that this treatment improved sleep quality [ 6 – 8 ].…”

Section: Introductionmentioning

confidence: 99%

Effect of a Standardized Extract of Asparagus officinalis Stem (ETAS®50) on Cognitive Function, Psychological Symptoms, and Behavior in Patients with Dementia: A Randomized Crossover Trial

Zenimoto,

Takahashi

2023

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Dementia is a disease of substantial national concern in a superaging society in Japan. Thus, the treatments targeting this disease are of high priority. However, pharmaceutical treatments are under development and invasive. Hence, many alternative treatments, which are less invasive, are tried, and some of them are supposed to work for dementia symptoms. ETAS®50 is one of these treatments. ETAS®50, a standardized extract of the Asparagus officinalis stem with heat shock protein-inducing activity, is a functional food. ETAS®50 has antistress, autonomic nerve regulation, and sleep quality improvement effects in humans and could contribute to relieving dementia symptoms. This double-blind crossover pilot trial aimed to examine the effects of ETAS®50. A total of 27 patients with mild-to-moderate dementia between October 2018 and February 2020 were included in the trial. ETAS®50 was consumed for 12 weeks and then a placebo for 12 weeks. A significant difference in the mean score of the severity of symptoms in the Neuropsychiatric Inventory Questionnaire (NPI-Q-a) was observed between the ETAS®50 period (0.56 ± 1.72 points) and placebo period (−0.67 ± 2.34 points) ( p = 0.045 ). Between-group comparisons with respect to the items of NPI-Q-a also showed a significant decrease in symptoms in the ETAS®50 period compared with the placebo period ( p = 0.015 for agitation and p = 0.045 for depression). In addition, we observed that scores for apathy tended to improve in the ETAS®50 period ( p = 0.058 ).

show abstract